Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Bank of America to hold a virtual conference » 04:55
05/15/20
05/15
04:55
05/15/20
04:55
HUM

Humana

$385.92 /

+7.59 (+2.01%)

, REGN

Regeneron

$569.80 /

-7.58 (-1.31%)

, CI

Cigna

$184.34 /

+3.05 (+1.68%)

, BAX

Baxter

$86.87 /

+1.33 (+1.55%)

, CLVS

Clovis

$9.55 /

+0.345 (+3.75%)

, SGEN

Seattle Genetics

$160.01 /

+2.22 (+1.41%)

, ATRC

AtriCure

$47.27 /

-1.52 (-3.12%)

, BLU

Bellus Health

$11.07 /

+0.51 (+4.83%)

, GWPH

GW Pharmaceuticals

$113.08 /

+2.625 (+2.38%)

, VCRA

Vocera

$18.33 /

-0.04 (-0.22%)

, EXEL

Exelixis

$24.75 /

-1.78 (-6.71%)

, AMED

Amedisys

$177.21 /

-2.59 (-1.44%)

, CARA

Cara Therapeutics

$15.15 /

+0.99 (+6.99%)

Bank of America…

Bank of America Healthcare Virtual Conference 2020 will be held on May 12-15.

ShowHide Related Items >><<
VCRA Vocera
$18.33 /

-0.04 (-0.22%)

SGEN Seattle Genetics
$160.01 /

+2.22 (+1.41%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

HUM Humana
$385.92 /

+7.59 (+2.01%)

GWPH GW Pharmaceuticals
$113.08 /

+2.625 (+2.38%)

EXEL Exelixis
$24.75 /

-1.78 (-6.71%)

CLVS Clovis
$9.55 /

+0.345 (+3.75%)

CI Cigna
$184.34 /

+3.05 (+1.68%)

CARA Cara Therapeutics
$15.15 /

+0.99 (+6.99%)

BLU Bellus Health
$11.07 /

+0.51 (+4.83%)

BAX Baxter
$86.87 /

+1.33 (+1.55%)

ATRC AtriCure
$47.27 /

-1.52 (-3.12%)

AMED Amedisys
$177.21 /

-2.59 (-1.44%)

HUM Humana
$385.92 /

+7.59 (+2.01%)

05/04/20 Mizuho
Humana price target raised to $420 from $405 at Mizuho
04/30/20 Credit Suisse
Humana price target raised to $423 from $400 at Credit Suisse
04/30/20 Oppenheimer
Humana price target raised to $425 from $400 at Oppenheimer
04/29/20 Cantor Fitzgerald
Humana comments on telephonic sales 'positive' for eHealth, says Cantor
REGN Regeneron
$569.80 /

-7.58 (-1.31%)

05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
05/06/20 BMO Capital
Regeneron price target raised to $525 from $466 at BMO Capital
05/06/20 SVB Leerink
Regeneron price target raised to $622 from $604 at SVB Leerink
CI Cigna
$184.34 /

+3.05 (+1.68%)

05/04/20 Bernstein
Cigna downgraded to Market Perform at Bernstein
05/04/20 Bernstein
Cigna downgraded to Market Perform from Outperform at Bernstein
05/04/20 Raymond James
Cigna price target raised to $240 from $210 at Raymond James
05/04/20 Deutsche Bank
Cigna price target lowered to $279 from $288 at Deutsche Bank
BAX Baxter
$86.87 /

+1.33 (+1.55%)

04/30/20 Piper Sandler
Baxter price target raised to $100 from $90 at Piper Sandler
04/20/20 Wells Fargo
Baxter price target raised to $104 from $92 at Wells Fargo
04/13/20 Raymond James
Baxter price target raised to $97 from $90 at Raymond James
03/19/20 Stifel
Baxter upgraded to Buy from Hold at Stifel
CLVS Clovis
$9.55 /

+0.345 (+3.75%)

05/06/20 H.C. Wainwright
Clovis price target raised to $29 from $27 at H.C. Wainwright
05/06/20 Piper Sandler
Clovis price target raised to $6 from $5.25 at Piper Sandler
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/27/20 SVB Leerink
Clovis downgraded to Underperform from Market Perform at SVB Leerink
SGEN Seattle Genetics
$160.01 /

+2.22 (+1.41%)

05/01/20
Fly Intel: Top five analyst upgrades
05/01/20 Guggenheim
Guggenheim upgrades Seattle Genetics to Buy on 40% sales growth potential
05/01/20 H.C. Wainwright
Seattle Genetics price target raised to $175 from $150 at H.C. Wainwright
05/01/20 Guggenheim
Seattle Genetics upgraded to Buy from Neutral at Guggenheim
ATRC AtriCure
$47.27 /

-1.52 (-3.12%)

05/11/20 BTIG
AtriCure price target raised to $56 from $45 at BTIG
05/11/20 Oppenheimer
AtriCure price target raised to $52 from $45 at Oppenheimer
05/08/20 Needham
AtriCure price target raised to $63 from $49 at Needham
05/05/20 Stifel
AtriCure should report positive outcome from CONVERGE trial shortly, says Stifel
BLU Bellus Health
$11.07 /

+0.51 (+4.83%)

01/08/20 Guggenheim
Horizon Therapeutics named Guggenheim's best Emerging Pharma idea for 2020
09/30/19
Fly Intel: Top five analyst initiations
09/30/19 Jefferies
Jefferies sees potential double in Bellus Health, starts shares at Buy
09/30/19 Guggenheim
Guggenheim starts Bellus Health at Buy with $12 price target
GWPH GW Pharmaceuticals
$113.08 /

+2.625 (+2.38%)

05/14/20 Cantor Fitzgerald
GW Pharmaceuticals price target raised to $154 from $120 at Cantor Fitzgerald
04/08/20 Northland
GW Pharmaceuticals initiated with an Outperform at Northland
03/06/20 Citi
Citi starts GW Pharmaceuticals at Buy, says recent pullback overdone
03/05/20 Citi
GW Pharmaceuticals initiated with a Buy at Citi
VCRA Vocera
$18.33 /

-0.04 (-0.22%)

04/24/20 SVB Leerink
Vocera price target lowered to $16 from $19 at SVB Leerink
04/24/20 Piper Sandler
Vocera an integral player in COVID-19 battle, says Piper Sandler
04/13/20 SVB Leerink
Vocera initiated with an Underperform at SVB Leerink
03/02/20 Guggenheim
Vocera price target raised to $29 after management meetings at Guggenheim
EXEL Exelixis
$24.75 /

-1.78 (-6.71%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
AMED Amedisys
$177.21 /

-2.59 (-1.44%)

05/11/20 Raymond James
Amedisys price target lowered to $210 from $225 at Raymond James
05/07/20 Benchmark
Amedisys downgraded to Hold on limited near-term visibility at Benchmark
05/07/20 Benchmark
Amedisys downgraded to Hold from Buy at Benchmark
03/09/20 Benchmark
Benchmark upgrades Amedisys to Buy on Home Health boost from crowded hospitals
CARA Cara Therapeutics
$15.15 /

+0.99 (+6.99%)

04/22/20 Cantor Fitzgerald
Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
04/21/20 H.C. Wainwright
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
01/10/20 Stifel
Cara Therapeutics named a BioPharma top pick for 2020 at Stifel
12/19/19 Piper Sandler
Cara Therapeutics risk/reward 'compelling' at these levels, says Piper Jaffray
VCRA Vocera
$18.33 /

-0.04 (-0.22%)

SGEN Seattle Genetics
$160.01 /

+2.22 (+1.41%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

HUM Humana
$385.92 /

+7.59 (+2.01%)

GWPH GW Pharmaceuticals
$113.08 /

+2.625 (+2.38%)

EXEL Exelixis
$24.75 /

-1.78 (-6.71%)

CLVS Clovis
$9.55 /

+0.345 (+3.75%)

CI Cigna
$184.34 /

+3.05 (+1.68%)

CARA Cara Therapeutics
$15.15 /

+0.99 (+6.99%)

BAX Baxter
$86.87 /

+1.33 (+1.55%)

ATRC AtriCure
$47.27 /

-1.52 (-3.12%)

AMED Amedisys
$177.21 /

-2.59 (-1.44%)

  • 12
    May
REGN Regeneron
$569.80 /

-7.58 (-1.31%)

HUM Humana
$385.92 /

+7.59 (+2.01%)

CLVS Clovis
$9.55 /

+0.345 (+3.75%)

VCRA Vocera
$18.33 /

-0.04 (-0.22%)

SGEN Seattle Genetics
$160.01 /

+2.22 (+1.41%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

HUM Humana
$385.92 /

+7.59 (+2.01%)

EXEL Exelixis
$24.75 /

-1.78 (-6.71%)

CLVS Clovis
$9.55 /

+0.345 (+3.75%)

CI Cigna
$184.34 /

+3.05 (+1.68%)

CARA Cara Therapeutics
$15.15 /

+0.99 (+6.99%)

BAX Baxter
$86.87 /

+1.33 (+1.55%)

AMED Amedisys
$177.21 /

-2.59 (-1.44%)

CLVS Clovis
$9.55 /

+0.345 (+3.75%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

HUM Humana
$385.92 /

+7.59 (+2.01%)

GWPH GW Pharmaceuticals
$113.08 /

+2.625 (+2.38%)

EXEL Exelixis
$24.75 /

-1.78 (-6.71%)

CLVS Clovis
$9.55 /

+0.345 (+3.75%)

CI Cigna
$184.34 /

+3.05 (+1.68%)

CARA Cara Therapeutics
$15.15 /

+0.99 (+6.99%)

BAX Baxter
$86.87 /

+1.33 (+1.55%)

Conference/Events
Bank of America to hold a virtual conference » 05:55
05/14/20
05/14
05:55
05/14/20
05:55
HUM

Humana

$378.33 /

-5.88 (-1.53%)

, REGN

Regeneron

$577.38 /

+20.24 (+3.63%)

, CI

Cigna

$181.29 /

-8.43 (-4.44%)

, BAX

Baxter

$85.54 /

-0.32 (-0.37%)

, CLVS

Clovis

$9.20 /

-0.34 (-3.56%)

, SGEN

Seattle Genetics

$157.79 /

-3.63 (-2.25%)

, ATRC

AtriCure

$48.79 /

+1.89 (+4.03%)

, BLU

Bellus Health

$10.56 /

-0.4 (-3.65%)

, GWPH

GW Pharmaceuticals

$110.46 /

-4.425 (-3.85%)

, VCRA

Vocera

$18.37 /

-0.3 (-1.61%)

, EXEL

Exelixis

$26.53 /

-0.33 (-1.23%)

, AMED

Amedisys

$179.80 /

+2.76 (+1.56%)

, CARA

Cara Therapeutics

$14.16 /

-0.97 (-6.41%)

Bank of America…

Bank of America Healthcare Virtual Conference 2020 will be held on May 12-15.

ShowHide Related Items >><<
VCRA Vocera
$18.37 /

-0.3 (-1.61%)

SGEN Seattle Genetics
$157.79 /

-3.63 (-2.25%)

REGN Regeneron
$577.38 /

+20.24 (+3.63%)

HUM Humana
$378.33 /

-5.88 (-1.53%)

GWPH GW Pharmaceuticals
$110.46 /

-4.425 (-3.85%)

EXEL Exelixis
$26.53 /

-0.33 (-1.23%)

CLVS Clovis
$9.20 /

-0.34 (-3.56%)

CI Cigna
$181.29 /

-8.43 (-4.44%)

CARA Cara Therapeutics
$14.16 /

-0.97 (-6.41%)

BLU Bellus Health
$10.56 /

-0.4 (-3.65%)

BAX Baxter
$85.54 /

-0.32 (-0.37%)

ATRC AtriCure
$48.79 /

+1.89 (+4.03%)

AMED Amedisys
$179.80 /

+2.76 (+1.56%)

HUM Humana
$378.33 /

-5.88 (-1.53%)

05/04/20 Mizuho
Humana price target raised to $420 from $405 at Mizuho
04/30/20 Credit Suisse
Humana price target raised to $423 from $400 at Credit Suisse
04/30/20 Oppenheimer
Humana price target raised to $425 from $400 at Oppenheimer
04/29/20 Cantor Fitzgerald
Humana comments on telephonic sales 'positive' for eHealth, says Cantor
REGN Regeneron
$577.38 /

+20.24 (+3.63%)

05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
05/06/20 BMO Capital
Regeneron price target raised to $525 from $466 at BMO Capital
05/06/20 SVB Leerink
Regeneron price target raised to $622 from $604 at SVB Leerink
05/06/20 Oppenheimer
Regeneron price target raised to $625 from $525 at Oppenheimer
CI Cigna
$181.29 /

-8.43 (-4.44%)

05/04/20 Bernstein
Cigna downgraded to Market Perform at Bernstein
05/04/20 Bernstein
Cigna downgraded to Market Perform from Outperform at Bernstein
05/04/20 Raymond James
Cigna price target raised to $240 from $210 at Raymond James
05/04/20 Deutsche Bank
Cigna price target lowered to $279 from $288 at Deutsche Bank
BAX Baxter
$85.54 /

-0.32 (-0.37%)

04/30/20 Piper Sandler
Baxter price target raised to $100 from $90 at Piper Sandler
04/20/20 Wells Fargo
Baxter price target raised to $104 from $92 at Wells Fargo
04/13/20 Raymond James
Baxter price target raised to $97 from $90 at Raymond James
03/19/20 Stifel
Baxter upgraded to Buy from Hold at Stifel
CLVS Clovis
$9.20 /

-0.34 (-3.56%)

05/06/20 H.C. Wainwright
Clovis price target raised to $29 from $27 at H.C. Wainwright
05/06/20 Piper Sandler
Clovis price target raised to $6 from $5.25 at Piper Sandler
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/27/20 SVB Leerink
Clovis downgraded to Underperform from Market Perform at SVB Leerink
SGEN Seattle Genetics
$157.79 /

-3.63 (-2.25%)

05/01/20
Fly Intel: Top five analyst upgrades
05/01/20 Guggenheim
Guggenheim upgrades Seattle Genetics to Buy on 40% sales growth potential
05/01/20 H.C. Wainwright
Seattle Genetics price target raised to $175 from $150 at H.C. Wainwright
05/01/20 Guggenheim
Seattle Genetics upgraded to Buy from Neutral at Guggenheim
ATRC AtriCure
$48.79 /

+1.89 (+4.03%)

05/11/20 BTIG
AtriCure price target raised to $56 from $45 at BTIG
05/11/20 Oppenheimer
AtriCure price target raised to $52 from $45 at Oppenheimer
05/08/20 Needham
AtriCure price target raised to $63 from $49 at Needham
05/05/20 Stifel
AtriCure should report positive outcome from CONVERGE trial shortly, says Stifel
BLU Bellus Health
$10.56 /

-0.4 (-3.65%)

01/08/20 Guggenheim
Horizon Therapeutics named Guggenheim's best Emerging Pharma idea for 2020
09/30/19
Fly Intel: Top five analyst initiations
09/30/19 Jefferies
Jefferies sees potential double in Bellus Health, starts shares at Buy
09/30/19 Guggenheim
Guggenheim starts Bellus Health at Buy with $12 price target
GWPH GW Pharmaceuticals
$110.46 /

-4.425 (-3.85%)

04/08/20 Northland
GW Pharmaceuticals initiated with an Outperform at Northland
03/06/20 Citi
Citi starts GW Pharmaceuticals at Buy, says recent pullback overdone
03/05/20 Citi
GW Pharmaceuticals initiated with a Buy at Citi
02/26/20 Oppenheimer
GW Pharmaceuticals price target lowered to $173 from $203 at Oppenheimer
VCRA Vocera
$18.37 /

-0.3 (-1.61%)

04/24/20 SVB Leerink
Vocera price target lowered to $16 from $19 at SVB Leerink
04/24/20 Piper Sandler
Vocera an integral player in COVID-19 battle, says Piper Sandler
04/13/20 SVB Leerink
Vocera initiated with an Underperform at SVB Leerink
03/02/20 Guggenheim
Vocera price target raised to $29 after management meetings at Guggenheim
EXEL Exelixis
$26.53 /

-0.33 (-1.23%)

05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
04/20/20 Piper Sandler
Exelixis combo approval would increase kidney cancer use, says Piper Sandler
AMED Amedisys
$179.80 /

+2.76 (+1.56%)

05/11/20 Raymond James
Amedisys price target lowered to $210 from $225 at Raymond James
05/07/20 Benchmark
Amedisys downgraded to Hold on limited near-term visibility at Benchmark
05/07/20 Benchmark
Amedisys downgraded to Hold from Buy at Benchmark
03/09/20 Benchmark
Benchmark upgrades Amedisys to Buy on Home Health boost from crowded hospitals
CARA Cara Therapeutics
$14.16 /

-0.97 (-6.41%)

04/22/20 Cantor Fitzgerald
Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
04/21/20 H.C. Wainwright
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
01/10/20 Stifel
Cara Therapeutics named a BioPharma top pick for 2020 at Stifel
12/19/19 Piper Sandler
Cara Therapeutics risk/reward 'compelling' at these levels, says Piper Jaffray
VCRA Vocera
$18.37 /

-0.3 (-1.61%)

SGEN Seattle Genetics
$157.79 /

-3.63 (-2.25%)

REGN Regeneron
$577.38 /

+20.24 (+3.63%)

HUM Humana
$378.33 /

-5.88 (-1.53%)

GWPH GW Pharmaceuticals
$110.46 /

-4.425 (-3.85%)

EXEL Exelixis
$26.53 /

-0.33 (-1.23%)

CLVS Clovis
$9.20 /

-0.34 (-3.56%)

CI Cigna
$181.29 /

-8.43 (-4.44%)

CARA Cara Therapeutics
$14.16 /

-0.97 (-6.41%)

BAX Baxter
$85.54 /

-0.32 (-0.37%)

ATRC AtriCure
$48.79 /

+1.89 (+4.03%)

AMED Amedisys
$179.80 /

+2.76 (+1.56%)

  • 12
    May
REGN Regeneron
$577.38 /

+20.24 (+3.63%)

HUM Humana
$378.33 /

-5.88 (-1.53%)

CLVS Clovis
$9.20 /

-0.34 (-3.56%)

VCRA Vocera
$18.37 /

-0.3 (-1.61%)

SGEN Seattle Genetics
$157.79 /

-3.63 (-2.25%)

REGN Regeneron
$577.38 /

+20.24 (+3.63%)

HUM Humana
$378.33 /

-5.88 (-1.53%)

EXEL Exelixis
$26.53 /

-0.33 (-1.23%)

CLVS Clovis
$9.20 /

-0.34 (-3.56%)

CI Cigna
$181.29 /

-8.43 (-4.44%)

CARA Cara Therapeutics
$14.16 /

-0.97 (-6.41%)

BAX Baxter
$85.54 /

-0.32 (-0.37%)

AMED Amedisys
$179.80 /

+2.76 (+1.56%)

CLVS Clovis
$9.20 /

-0.34 (-3.56%)

REGN Regeneron
$577.38 /

+20.24 (+3.63%)

HUM Humana
$378.33 /

-5.88 (-1.53%)

GWPH GW Pharmaceuticals
$110.46 /

-4.425 (-3.85%)

EXEL Exelixis
$26.53 /

-0.33 (-1.23%)

CLVS Clovis
$9.20 /

-0.34 (-3.56%)

CI Cigna
$181.29 /

-8.43 (-4.44%)

CARA Cara Therapeutics
$14.16 /

-0.97 (-6.41%)

BAX Baxter
$85.54 /

-0.32 (-0.37%)

Conference/Events
Bank of America to hold a virtual conference » 04:55
05/13/20
05/13
04:55
05/13/20
04:55
HUM

Humana

$384.21 /

+4.25 (+1.12%)

, REGN

Regeneron

$557.14 /

-16.97 (-2.96%)

, CI

Cigna

$189.72 /

+0.78 (+0.41%)

, BAX

Baxter

$85.86 /

-3.07 (-3.45%)

, CLVS

Clovis

$9.54 /

+0.29 (+3.14%)

, SGEN

Seattle Genetics

$161.42 /

+0.33 (+0.20%)

, ATRC

AtriCure

$46.90 /

+0.86 (+1.87%)

, BLU

Bellus Health

$10.96 /

+0.68 (+6.61%)

, GWPH

GW Pharmaceuticals

$114.88 /

+6.1 (+5.61%)

, VCRA

Vocera

$18.67 /

-0.09 (-0.48%)

, EXEL

Exelixis

$26.86 /

-0.58 (-2.11%)

, AMED

Amedisys

$177.04 /

-1.41 (-0.79%)

, CARA

Cara Therapeutics

$15.13 /

-0.67 (-4.24%)

Bank of America…

Bank of America Healthcare Virtual Conference 2020 will be held on May 12-15.

ShowHide Related Items >><<
VCRA Vocera
$18.67 /

-0.09 (-0.48%)

SGEN Seattle Genetics
$161.42 /

+0.33 (+0.20%)

REGN Regeneron
$557.14 /

-16.97 (-2.96%)

HUM Humana
$384.21 /

+4.25 (+1.12%)

GWPH GW Pharmaceuticals
$114.88 /

+6.1 (+5.61%)

EXEL Exelixis
$26.86 /

-0.58 (-2.11%)

CLVS Clovis
$9.54 /

+0.29 (+3.14%)

CI Cigna
$189.72 /

+0.78 (+0.41%)

CARA Cara Therapeutics
$15.13 /

-0.67 (-4.24%)

BLU Bellus Health
$10.96 /

+0.68 (+6.61%)

BAX Baxter
$85.86 /

-3.07 (-3.45%)

ATRC AtriCure
$46.90 /

+0.86 (+1.87%)

AMED Amedisys
$177.04 /

-1.41 (-0.79%)

HUM Humana
$384.21 /

+4.25 (+1.12%)

05/04/20 Mizuho
Humana price target raised to $420 from $405 at Mizuho
04/30/20 Credit Suisse
Humana price target raised to $423 from $400 at Credit Suisse
04/30/20 Oppenheimer
Humana price target raised to $425 from $400 at Oppenheimer
04/29/20 Cantor Fitzgerald
Humana comments on telephonic sales 'positive' for eHealth, says Cantor
REGN Regeneron
$557.14 /

-16.97 (-2.96%)

05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
05/06/20 BMO Capital
Regeneron price target raised to $525 from $466 at BMO Capital
05/06/20 SVB Leerink
Regeneron price target raised to $622 from $604 at SVB Leerink
05/06/20 Oppenheimer
Regeneron price target raised to $625 from $525 at Oppenheimer
CI Cigna
$189.72 /

+0.78 (+0.41%)

05/04/20 Bernstein
Cigna downgraded to Market Perform at Bernstein
05/04/20 Bernstein
Cigna downgraded to Market Perform from Outperform at Bernstein
05/04/20 Raymond James
Cigna price target raised to $240 from $210 at Raymond James
05/04/20 Deutsche Bank
Cigna price target lowered to $279 from $288 at Deutsche Bank
BAX Baxter
$85.86 /

-3.07 (-3.45%)

04/30/20 Piper Sandler
Baxter price target raised to $100 from $90 at Piper Sandler
04/20/20 Wells Fargo
Baxter price target raised to $104 from $92 at Wells Fargo
04/13/20 Raymond James
Baxter price target raised to $97 from $90 at Raymond James
03/19/20 Stifel
Baxter upgraded to Buy from Hold at Stifel
CLVS Clovis
$9.54 /

+0.29 (+3.14%)

05/06/20 H.C. Wainwright
Clovis price target raised to $29 from $27 at H.C. Wainwright
05/06/20 Piper Sandler
Clovis price target raised to $6 from $5.25 at Piper Sandler
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/27/20 SVB Leerink
Clovis downgraded to Underperform from Market Perform at SVB Leerink
SGEN Seattle Genetics
$161.42 /

+0.33 (+0.20%)

05/01/20
Fly Intel: Top five analyst upgrades
05/01/20 Guggenheim
Guggenheim upgrades Seattle Genetics to Buy on 40% sales growth potential
05/01/20 H.C. Wainwright
Seattle Genetics price target raised to $175 from $150 at H.C. Wainwright
05/01/20 Guggenheim
Seattle Genetics upgraded to Buy from Neutral at Guggenheim
ATRC AtriCure
$46.90 /

+0.86 (+1.87%)

05/11/20 BTIG
AtriCure price target raised to $56 from $45 at BTIG
05/11/20 Oppenheimer
AtriCure price target raised to $52 from $45 at Oppenheimer
05/08/20 Needham
AtriCure price target raised to $63 from $49 at Needham
05/05/20 Stifel
AtriCure should report positive outcome from CONVERGE trial shortly, says Stifel
BLU Bellus Health
$10.96 /

+0.68 (+6.61%)

01/08/20 Guggenheim
Horizon Therapeutics named Guggenheim's best Emerging Pharma idea for 2020
09/30/19
Fly Intel: Top five analyst initiations
09/30/19 Jefferies
Jefferies sees potential double in Bellus Health, starts shares at Buy
09/30/19 Guggenheim
Guggenheim starts Bellus Health at Buy with $12 price target
GWPH GW Pharmaceuticals
$114.88 /

+6.1 (+5.61%)

04/08/20 Northland
GW Pharmaceuticals initiated with an Outperform at Northland
03/06/20 Citi
Citi starts GW Pharmaceuticals at Buy, says recent pullback overdone
03/05/20 Citi
GW Pharmaceuticals initiated with a Buy at Citi
02/26/20 Oppenheimer
GW Pharmaceuticals price target lowered to $173 from $203 at Oppenheimer
VCRA Vocera
$18.67 /

-0.09 (-0.48%)

04/24/20 SVB Leerink
Vocera price target lowered to $16 from $19 at SVB Leerink
04/24/20 Piper Sandler
Vocera an integral player in COVID-19 battle, says Piper Sandler
04/13/20 SVB Leerink
Vocera initiated with an Underperform at SVB Leerink
03/02/20 Guggenheim
Vocera price target raised to $29 after management meetings at Guggenheim
EXEL Exelixis
$26.86 /

-0.58 (-2.11%)

05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
04/20/20 Piper Sandler
Exelixis combo approval would increase kidney cancer use, says Piper Sandler
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
AMED Amedisys
$177.04 /

-1.41 (-0.79%)

05/11/20 Raymond James
Amedisys price target lowered to $210 from $225 at Raymond James
05/07/20 Benchmark
Amedisys downgraded to Hold on limited near-term visibility at Benchmark
05/07/20 Benchmark
Amedisys downgraded to Hold from Buy at Benchmark
03/09/20 Benchmark
Benchmark upgrades Amedisys to Buy on Home Health boost from crowded hospitals
CARA Cara Therapeutics
$15.13 /

-0.67 (-4.24%)

04/22/20 Cantor Fitzgerald
Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
04/21/20 H.C. Wainwright
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
01/10/20 Stifel
Cara Therapeutics named a BioPharma top pick for 2020 at Stifel
12/19/19 Piper Sandler
Cara Therapeutics risk/reward 'compelling' at these levels, says Piper Jaffray
VCRA Vocera
$18.67 /

-0.09 (-0.48%)

SGEN Seattle Genetics
$161.42 /

+0.33 (+0.20%)

REGN Regeneron
$557.14 /

-16.97 (-2.96%)

HUM Humana
$384.21 /

+4.25 (+1.12%)

GWPH GW Pharmaceuticals
$114.88 /

+6.1 (+5.61%)

EXEL Exelixis
$26.86 /

-0.58 (-2.11%)

CLVS Clovis
$9.54 /

+0.29 (+3.14%)

CI Cigna
$189.72 /

+0.78 (+0.41%)

CARA Cara Therapeutics
$15.13 /

-0.67 (-4.24%)

BAX Baxter
$85.86 /

-3.07 (-3.45%)

ATRC AtriCure
$46.90 /

+0.86 (+1.87%)

AMED Amedisys
$177.04 /

-1.41 (-0.79%)

  • 12
    May
REGN Regeneron
$557.14 /

-16.97 (-2.96%)

HUM Humana
$384.21 /

+4.25 (+1.12%)

CLVS Clovis
$9.54 /

+0.29 (+3.14%)

VCRA Vocera
$18.67 /

-0.09 (-0.48%)

SGEN Seattle Genetics
$161.42 /

+0.33 (+0.20%)

REGN Regeneron
$557.14 /

-16.97 (-2.96%)

HUM Humana
$384.21 /

+4.25 (+1.12%)

EXEL Exelixis
$26.86 /

-0.58 (-2.11%)

CLVS Clovis
$9.54 /

+0.29 (+3.14%)

CI Cigna
$189.72 /

+0.78 (+0.41%)

CARA Cara Therapeutics
$15.13 /

-0.67 (-4.24%)

BAX Baxter
$85.86 /

-3.07 (-3.45%)

AMED Amedisys
$177.04 /

-1.41 (-0.79%)

CLVS Clovis
$9.54 /

+0.29 (+3.14%)

REGN Regeneron
$557.14 /

-16.97 (-2.96%)

HUM Humana
$384.21 /

+4.25 (+1.12%)

GWPH GW Pharmaceuticals
$114.88 /

+6.1 (+5.61%)

EXEL Exelixis
$26.86 /

-0.58 (-2.11%)

CLVS Clovis
$9.54 /

+0.29 (+3.14%)

CI Cigna
$189.72 /

+0.78 (+0.41%)

CARA Cara Therapeutics
$15.13 /

-0.67 (-4.24%)

BAX Baxter
$85.86 /

-3.07 (-3.45%)

Conference/Events
Bank of America to hold a virtual conference » 08:46
05/12/20
05/12
08:46
05/12/20
08:46
HUM

Humana

$379.96 /

+2.34 (+0.62%)

, REGN

Regeneron

$574.11 /

+11.44 (+2.03%)

, CI

Cigna

$188.94 /

-0.15 (-0.08%)

, BAX

Baxter

$88.93 /

+0.89 (+1.01%)

, CLVS

Clovis

$9.25 /

+0.23 (+2.55%)

, SGEN

Seattle Genetics

$161.09 /

+4 (+2.55%)

, ATRC

AtriCure

$46.04 /

+0.86 (+1.90%)

, BLU

Bellus Health

$10.28 /

+0.01 (+0.10%)

, GWPH

GW Pharmaceuticals

$108.78 /

+0.27 (+0.25%)

, VCRA

Vocera

$18.76 /

+0.22 (+1.19%)

, EXEL

Exelixis

$27.44 /

+1.445 (+5.56%)

, AMED

Amedisys

$178.45 /

-1.52 (-0.84%)

, CARA

Cara Therapeutics

$15.80 /

+1.63 (+11.50%)

Bank of America…

Bank of America Healthcare Virtual Conference 2020 will be held on May 12-15.

ShowHide Related Items >><<
VCRA Vocera
$18.76 /

+0.22 (+1.19%)

SGEN Seattle Genetics
$161.09 /

+4 (+2.55%)

REGN Regeneron
$574.11 /

+11.44 (+2.03%)

HUM Humana
$379.96 /

+2.34 (+0.62%)

GWPH GW Pharmaceuticals
$108.78 /

+0.27 (+0.25%)

EXEL Exelixis
$27.44 /

+1.445 (+5.56%)

CLVS Clovis
$9.25 /

+0.23 (+2.55%)

CI Cigna
$188.94 /

-0.15 (-0.08%)

CARA Cara Therapeutics
$15.80 /

+1.63 (+11.50%)

BLU Bellus Health
$10.28 /

+0.01 (+0.10%)

BAX Baxter
$88.93 /

+0.89 (+1.01%)

ATRC AtriCure
$46.04 /

+0.86 (+1.90%)

AMED Amedisys
$178.45 /

-1.52 (-0.84%)

HUM Humana
$379.96 /

+2.34 (+0.62%)

05/04/20 Mizuho
Humana price target raised to $420 from $405 at Mizuho
04/30/20 Credit Suisse
Humana price target raised to $423 from $400 at Credit Suisse
04/30/20 Oppenheimer
Humana price target raised to $425 from $400 at Oppenheimer
04/29/20 Cantor Fitzgerald
Humana comments on telephonic sales 'positive' for eHealth, says Cantor
REGN Regeneron
$574.11 /

+11.44 (+2.03%)

05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
05/06/20 BMO Capital
Regeneron price target raised to $525 from $466 at BMO Capital
05/06/20 SVB Leerink
Regeneron price target raised to $622 from $604 at SVB Leerink
05/06/20 Oppenheimer
Regeneron price target raised to $625 from $525 at Oppenheimer
CI Cigna
$188.94 /

-0.15 (-0.08%)

05/04/20 Bernstein
Cigna downgraded to Market Perform at Bernstein
05/04/20 Bernstein
Cigna downgraded to Market Perform from Outperform at Bernstein
05/04/20 Raymond James
Cigna price target raised to $240 from $210 at Raymond James
05/04/20 Deutsche Bank
Cigna price target lowered to $279 from $288 at Deutsche Bank
BAX Baxter
$88.93 /

+0.89 (+1.01%)

04/30/20 Piper Sandler
Baxter price target raised to $100 from $90 at Piper Sandler
04/20/20 Wells Fargo
Baxter price target raised to $104 from $92 at Wells Fargo
04/13/20 Raymond James
Baxter price target raised to $97 from $90 at Raymond James
03/19/20 Stifel
Baxter upgraded to Buy from Hold at Stifel
CLVS Clovis
$9.25 /

+0.23 (+2.55%)

05/06/20 H.C. Wainwright
Clovis price target raised to $29 from $27 at H.C. Wainwright
05/06/20 Piper Sandler
Clovis price target raised to $6 from $5.25 at Piper Sandler
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/27/20 SVB Leerink
Clovis downgraded to Underperform from Market Perform at SVB Leerink
SGEN Seattle Genetics
$161.09 /

+4 (+2.55%)

05/01/20
Fly Intel: Top five analyst upgrades
05/01/20 Guggenheim
Guggenheim upgrades Seattle Genetics to Buy on 40% sales growth potential
05/01/20 H.C. Wainwright
Seattle Genetics price target raised to $175 from $150 at H.C. Wainwright
05/01/20 Guggenheim
Seattle Genetics upgraded to Buy from Neutral at Guggenheim
ATRC AtriCure
$46.04 /

+0.86 (+1.90%)

05/11/20 BTIG
AtriCure price target raised to $56 from $45 at BTIG
05/11/20 Oppenheimer
AtriCure price target raised to $52 from $45 at Oppenheimer
05/08/20 Needham
AtriCure price target raised to $63 from $49 at Needham
05/05/20 Stifel
AtriCure should report positive outcome from CONVERGE trial shortly, says Stifel
BLU Bellus Health
$10.28 /

+0.01 (+0.10%)

01/08/20 Guggenheim
Horizon Therapeutics named Guggenheim's best Emerging Pharma idea for 2020
09/30/19
Fly Intel: Top five analyst initiations
09/30/19 Jefferies
Jefferies sees potential double in Bellus Health, starts shares at Buy
09/30/19 Guggenheim
Guggenheim starts Bellus Health at Buy with $12 price target
GWPH GW Pharmaceuticals
$108.78 /

+0.27 (+0.25%)

04/08/20 Northland
GW Pharmaceuticals initiated with an Outperform at Northland
03/06/20 Citi
Citi starts GW Pharmaceuticals at Buy, says recent pullback overdone
03/05/20 Citi
GW Pharmaceuticals initiated with a Buy at Citi
02/26/20 Oppenheimer
GW Pharmaceuticals price target lowered to $173 from $203 at Oppenheimer
VCRA Vocera
$18.76 /

+0.22 (+1.19%)

04/24/20 SVB Leerink
Vocera price target lowered to $16 from $19 at SVB Leerink
04/24/20 Piper Sandler
Vocera an integral player in COVID-19 battle, says Piper Sandler
04/13/20 SVB Leerink
Vocera initiated with an Underperform at SVB Leerink
03/02/20 Guggenheim
Vocera price target raised to $29 after management meetings at Guggenheim
EXEL Exelixis
$27.44 /

+1.445 (+5.56%)

05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
04/20/20 Piper Sandler
Exelixis combo approval would increase kidney cancer use, says Piper Sandler
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
AMED Amedisys
$178.45 /

-1.52 (-0.84%)

05/11/20 Raymond James
Amedisys price target lowered to $210 from $225 at Raymond James
05/07/20 Benchmark
Amedisys downgraded to Hold on limited near-term visibility at Benchmark
05/07/20 Benchmark
Amedisys downgraded to Hold from Buy at Benchmark
03/09/20 Benchmark
Benchmark upgrades Amedisys to Buy on Home Health boost from crowded hospitals
CARA Cara Therapeutics
$15.80 /

+1.63 (+11.50%)

04/22/20 Cantor Fitzgerald
Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
04/21/20 H.C. Wainwright
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
01/10/20 Stifel
Cara Therapeutics named a BioPharma top pick for 2020 at Stifel
12/19/19 Piper Sandler
Cara Therapeutics risk/reward 'compelling' at these levels, says Piper Jaffray
VCRA Vocera
$18.76 /

+0.22 (+1.19%)

SGEN Seattle Genetics
$161.09 /

+4 (+2.55%)

REGN Regeneron
$574.11 /

+11.44 (+2.03%)

HUM Humana
$379.96 /

+2.34 (+0.62%)

GWPH GW Pharmaceuticals
$108.78 /

+0.27 (+0.25%)

EXEL Exelixis
$27.44 /

+1.445 (+5.56%)

CLVS Clovis
$9.25 /

+0.23 (+2.55%)

CI Cigna
$188.94 /

-0.15 (-0.08%)

CARA Cara Therapeutics
$15.80 /

+1.63 (+11.50%)

BAX Baxter
$88.93 /

+0.89 (+1.01%)

ATRC AtriCure
$46.04 /

+0.86 (+1.90%)

AMED Amedisys
$178.45 /

-1.52 (-0.84%)

  • 12
    May
REGN Regeneron
$574.11 /

+11.44 (+2.03%)

HUM Humana
$379.96 /

+2.34 (+0.62%)

CLVS Clovis
$9.25 /

+0.23 (+2.55%)

VCRA Vocera
$18.76 /

+0.22 (+1.19%)

SGEN Seattle Genetics
$161.09 /

+4 (+2.55%)

REGN Regeneron
$574.11 /

+11.44 (+2.03%)

HUM Humana
$379.96 /

+2.34 (+0.62%)

EXEL Exelixis
$27.44 /

+1.445 (+5.56%)

CLVS Clovis
$9.25 /

+0.23 (+2.55%)

CI Cigna
$188.94 /

-0.15 (-0.08%)

CARA Cara Therapeutics
$15.80 /

+1.63 (+11.50%)

BAX Baxter
$88.93 /

+0.89 (+1.01%)

AMED Amedisys
$178.45 /

-1.52 (-0.84%)

CLVS Clovis
$9.25 /

+0.23 (+2.55%)

REGN Regeneron
$574.11 /

+11.44 (+2.03%)

HUM Humana
$379.96 /

+2.34 (+0.62%)

GWPH GW Pharmaceuticals
$108.78 /

+0.27 (+0.25%)

EXEL Exelixis
$27.44 /

+1.445 (+5.56%)

CLVS Clovis
$9.25 /

+0.23 (+2.55%)

CI Cigna
$188.94 /

-0.15 (-0.08%)

CARA Cara Therapeutics
$15.80 /

+1.63 (+11.50%)

BAX Baxter
$88.93 /

+0.89 (+1.01%)

Syndicate
AtriCure 3.98M share Secondary priced at $44.00 » 20:24
05/11/20
05/11
20:24
05/11/20
20:24
ATRC

AtriCure

$46.04 /

+0.86 (+1.90%)

The deal size was…

The deal size was increased from $100M to $175M and priced below the last closing price of $46.03. JPMorgan and Piper Sandler are acting as joint book running managers for the offering.

ShowHide Related Items >><<
ATRC AtriCure
$46.04 /

+0.86 (+1.90%)

ATRC AtriCure
$46.04 /

+0.86 (+1.90%)

05/11/20 BTIG
AtriCure price target raised to $56 from $45 at BTIG
05/11/20 Oppenheimer
AtriCure price target raised to $52 from $45 at Oppenheimer
05/08/20 Needham
AtriCure price target raised to $63 from $49 at Needham
05/05/20 Stifel
AtriCure should report positive outcome from CONVERGE trial shortly, says Stifel
ATRC AtriCure
$46.04 /

+0.86 (+1.90%)

  • 12
    May
Recommendations
AtriCure price target raised to $56 from $45 at BTIG » 09:18
05/11/20
05/11
09:18
05/11/20
09:18
ATRC

AtriCure

$45.18 /

+3.31 (+7.91%)

BTIG analyst Marie…

BTIG analyst Marie Thibault raised the firm's price target on AtriCure to $56 from $45 and keeps a Buy rating on the shares. The analyst believes that the results from the company's CONVERGE IDE clinical trial may increase the penetration of the hybrid Convergent procedure for patients with persistent atrial fibrillation, turning "incrementally more confident" that the FDA panel and approval process will go smoothly.

ShowHide Related Items >><<
ATRC AtriCure
$45.18 /

+3.31 (+7.91%)

05/11/20 Oppenheimer
AtriCure price target raised to $52 from $45 at Oppenheimer
05/08/20 Needham
AtriCure price target raised to $63 from $49 at Needham
05/05/20 Stifel
AtriCure should report positive outcome from CONVERGE trial shortly, says Stifel
04/28/20 Piper Sandler
Untreated heart attacks negative for Abiomed, says Piper Sandler
  • 12
    May
Recommendations
AtriCure price target raised to $52 from $45 at Oppenheimer » 08:49
05/11/20
05/11
08:49
05/11/20
08:49
ATRC

AtriCure

$45.18 /

+3.31 (+7.91%)

Oppenheimer analyst Suraj…

Oppenheimer analyst Suraj Kalia raised the firm's price target on AtriCure to $52 from $45 and keeps an Outperform rating on the shares. The analyst notes that AtriCure's CONVERGE pivotal RCT evaluating a hybrid epi+endo ablation same day approach, to endo alone in persistent AF patients showed a 23% improvement in greater than90% reduction in AF burden at 12 months for the hybrid approach versus endo ablation alone. CONVERGE, he contends, has answered the question of improved outcomes using the hybrid approach. Expectations are for an FDA panel later in 2020, with approval thereafter, Kalia adds. The analyst believes the label and potential inclusion in HRS guidelines would be critical to faster adoption.

ShowHide Related Items >><<
ATRC AtriCure
$45.18 /

+3.31 (+7.91%)

05/08/20 Needham
AtriCure price target raised to $63 from $49 at Needham
05/05/20 Stifel
AtriCure should report positive outcome from CONVERGE trial shortly, says Stifel
04/28/20 Piper Sandler
Untreated heart attacks negative for Abiomed, says Piper Sandler
04/09/20 Piper Sandler
AtriCure should weather disruption 'quite well,' says Piper Sandler
  • 12
    May
Syndicate
AtriCure announces $100M stock offering » 08:28
05/11/20
05/11
08:28
05/11/20
08:28
ATRC

AtriCure

$45.18 /

+3.31 (+7.91%)

JPMorgan and Piper…

JPMorgan and Piper Sandler are acting as joint book running managers for the offering.

ShowHide Related Items >><<
ATRC AtriCure
$45.18 /

+3.31 (+7.91%)

05/08/20 Needham
AtriCure price target raised to $63 from $49 at Needham
05/05/20 Stifel
AtriCure should report positive outcome from CONVERGE trial shortly, says Stifel
04/28/20 Piper Sandler
Untreated heart attacks negative for Abiomed, says Piper Sandler
04/09/20 Piper Sandler
AtriCure should weather disruption 'quite well,' says Piper Sandler
Recommendations
AtriCure price target raised to $63 from $49 at Needham » 15:45
05/08/20
05/08
15:45
05/08/20
15:45
ATRC

AtriCure

$44.98 /

+3.11 (+7.43%)

Needham analyst Mike…

Needham analyst Mike Matson raised the firm's price target on AtriCure to $63 from $49 and reiterated a Buy rating on the shares following the company's CONVERGE trial meeting both its primary efficacy and safety endpoints. Matson sees the results increasing the likelihood of FDA approval for Convergent, and expects the next step to be an FDA panel meeting later this year.

ShowHide Related Items >><<
ATRC AtriCure
$44.98 /

+3.11 (+7.43%)

05/05/20 Stifel
AtriCure should report positive outcome from CONVERGE trial shortly, says Stifel
04/28/20 Piper Sandler
Untreated heart attacks negative for Abiomed, says Piper Sandler
04/09/20 Piper Sandler
AtriCure should weather disruption 'quite well,' says Piper Sandler
04/06/20 Oppenheimer
AtriCure initiated with an Outperform at Oppenheimer
Conference/Events
AtriCure to hold a webcast » 12:25
05/08/20
05/08
12:25
05/08/20
12:25
ATRC

AtriCure

$44.92 /

+3.05 (+7.28%)

Management provides an…

Management provides an analyst and institutional investor update to coincide with the 41st Annual Heart Rhythm Scientific Sessions on May 8 at 1 pm. Webcast Link

ShowHide Related Items >><<
ATRC AtriCure
$44.92 /

+3.05 (+7.28%)

05/05/20 Stifel
AtriCure should report positive outcome from CONVERGE trial shortly, says Stifel
04/28/20 Piper Sandler
Untreated heart attacks negative for Abiomed, says Piper Sandler
04/09/20 Piper Sandler
AtriCure should weather disruption 'quite well,' says Piper Sandler
04/06/20 Oppenheimer
AtriCure initiated with an Outperform at Oppenheimer

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.